Watch for Adakveo or Oxbryta to Treat Sickle Cell Disease

Adakveo (ah-DAK-vee-oh, crizanlizumab) and Oxbryta (oks-BRYE-tuh, voxelotor) will be new meds for sickle cell disease.

They may be added to hydroxyurea...the first-line option to reduce pain crises, hospitalizations, and possibly improve survival.

And they'll compete with oral Endari (L-glutamine)...which seems to reduce pain crises and possibly hospitalizations.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote